Comparison of Electrocardiographic Changes Induced by Injection Meglumine Antimoniate after Intravenous Versus Intramuscular Administration in Patients of Cutaneous Leishmaniasis

Shafia Shaikh; Najia Ahmed; Hafiz Muhammad Umer; Moniba  Saeed

doi:10.51253/pafmj.v76iSUPPL-8.14124

Authors

Shafia Shaikh Department of Dermatology, Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan
Najia Ahmed Department of Dermatology, Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan
Hafiz Muhammad Umer Department of Medicine, Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan
Moniba Saeed Department of Dermatology, Combined Military Hospital Quetta/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-8.14124

Keywords:

Cutaneous Leishmaniasis, ECG, Meglumine Antimoniate, Sandfly

Abstract

Objective: To compare the electrocardiographic changes induced after intravenous versus intramuscular administration of injection meglumine antimoniate in patients with cutaneous leishmaniasis.

Study Design: Quasi Experimental Study.

Place and Duration of Study: Department of Dermatology, Combined Military Hospital, Quetta Pakistan, from April to October 2024.

Methodology: A total of 80 patients with biopsy-proven cutaneous leishmaniasis were divided into intravenous (Group-A) and intramuscular (Group-B) groups. The intravenous group received 15mg/kg/day of meglumine antimoniate diluted in 100 ml of 5% glucose solution over 60 minutes with cardiac monitoring, while the intramuscular group received a similar dose as per weight into the gluteal muscles. ECG was done before the start of treatment and then weekly. Only 03 patients lost to follow so data analysis was done on 77 patients.

Results: Mean age of the patients was 30.60±6.35 years. Out of 77, 24(30.0%) patients experienced ECG changes in both groups: T wave inversion in 14(17.5%), Bifid T-wave in 4(5.0%), and QT prolongation in 2(2.5%). A higher proportion of ECG changes occurred in the Group-A (n=14, 35.0%) compared to the Group-B (n=10, 25.0%), but the difference was not statistically significant (p=0.210). The ECG changes were statistically insignificant when stratified for route of administration, number of lesions, and number of injections except for QT prolongation (p=0.004)

Conclusion: Electrocardiographic changes were more frequent in patients using the intravenous route compared to intramuscular administration, but the results were statistically insignificant.

Downloads

Download data is not yet available.

References

1. Ghatee MA, Sharifi I, Mohammadi N, Moghaddam BE, Kohansal MH. Geographical and climatic risk factors of cutaneous leishmaniasis in the hyper-endemic focus of Bam County in southeast Iran. Front Public Health 2023; 11: 1236552.

https://doi.org/10.3389/fpubh.2023.1236552

2. Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM, Gilaberte Y. Cutaneous and Mucocutaneous Leishmaniasis. Actas Dermosifiliogr 2021; S0001-7310(21)00108-3: S1578-2190.

https://doi.org/10.1016/j.ad.2021.02.008

3. Uribe-Restrepo AF, Prieto MD, Cossio A, Desai MM, del Mar CM. Eligibility for local therapies in adolescents and adults with cutaneous Leishmaniasis from southwestern Colombia: a cross-sectional study. Am J Trop Med Hyg 2019; 100(2): 306-310.

https://doi.org/10.4269/ajtmh.18-0643.

4. Ahmed N, Malik S, Tahir M, Rahman A, Fayyaz I, Raza N, et al. Comparison of oral dapsone with intramuscular meglumine antimoniate in cutaneous leishmaniasis. J Ayub Med Coll Abbottabad 2022; 34(4): 802-806.

https://doi.org/10.55519/JAMC-04-10265

5. World Health Organization. (2014). Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region. [cited January 5th 2025] Available from:

https://www.who.int/publications/i/item/9789290219453

6. Saffarian Z, Razavi Z, Ghanadan A. Erysipeloid leishmaniasis, a rare case of atypical cutaneous leishmaniasis misdiagnosed initially as rosacea. JAAD Case Rep 2025; 60: 15-18.

https://doi.org/10.1016/j.jdcr.2025.01.048

7. Martin R, Lee VR. Antimony toxicity [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Apr 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK608003

8. Gonçalves RS, Ladeira RT, Garcia AF, Teixeira Júnior P, Dias BK, Côrtes MA. Electrocardiographic changes in patients with American tegumentary leishmaniasis treated with meglumine antimoniate: integrative review. J Medicine Biomedical Sci 2021; 20(1): 131-136. https://doi.org/10.9771/cmbio.v20i1.37087

9. Ghandi Y, Mehrabi S, Safaei M. Electrocardiography Adverse Effects Systemic Glucantime in a Child With Cutaneous Leishmaniosis: A Case Report and Brief Review. J Pediatr Rev 2022; 10(2): 155-160. http://dx.doi.org/10.32598/jpr.10.2.913.3

10. Afridi IU, Bibi S, Shiraz Z, Ullah N, Khan WZ, Khan M. Effects of systemic meglumine antimoniate on ECG in patients with cutaneous leishmaniasis. J Pak Assoc Dermatol 2024; 34(4): 829-835. https://doi.org/10.66344/jpad.34.4.2024.2840

11. Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singap 2008; 37(11): 916-918.

12. Tahir M, Bashir U, Ahmed N, Mumtaz J. Electrocardiographic changes with standard dose of meglumine antimoniate therapy in cutaneous leishmaniasis. Pak Armed Forces Med J 2021; 71(4): 1235-1238.

https://doi.org/10.51253/pafmj.v71i4.4048

13. Antezana G, Zeballos R, Mendoza C, Lyevre P, Valda L, Cardenas F, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86(1): 31-33. https://doi.org/10.1016/0035-9203(92)90427-e

14. Abid R, Haleem S, Ghani S, Ahmed N, Farman M, Bukhari M, et al. Electrocardiographic changes during treatment with cutaneous leishmaniasis. Pak Heart J 2013; 46(1): 51-56.

https://doi.org/10.47144/phj.v46i1

15. Shanehsaz SM, Ishkhanian S. Electrocardiographic and biochemical adverse effects of meglumine antimoniate (MA) during treatment of Syrian cutaneous leishmaniasis patients. J Pak Assoc Dermatol 2013; 23(4): 412-417.

https://doi.org/10.66344/jpad.23.4.2013.289

16. Daadaa N, Youssef S, Haggui A, Harbaoui S, Jaber K, Doss N, et al. New onset of sinoatrial block in a young patient treated with systemic meglumine antimoniate. Clin Case Rep 2021; 9(3): 1797-1798. https://doi.org/10.1002/ccr3.3768

17. Salah NB, Aounallah A, Manaa L, Lahouel M, Mkhinini H, Belajouza C, et al. Systemic meglumine antimoniate‐induced severe dilated cardiomyopathy. Dermatol Ther 2022; 35(12): e15896. https://doi.org/10.1111/dth.15896

18. Rodrigues BC, Ferreira MF, Barroso DH, da Motta JO, de Paula CD, Porto C, et al. A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist 2020; 14: 257-263.

https://doi.org/10.1016/j.ijpddr.2020.11.002

19. Lyra MR, Oliveira LF, Schubach AO, Sampaio RN, Rodrigues BC, Hueb M, et al. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil. Clin Infect Dis 2023; 77(4): 574-582.

https://doi.org/10.1093/cid/ciad253

20. Carvalho SH, Frézard F, Pereira NP, Moura AS, Ramos LM, Carvalho GB, et al. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short‐term possibilities for an alternative treatment. Trop Med Int Health 2019; 24(4): 380-391. https://doi.org/10.1111/tmi.13210